Compare Crispr Therapeutics AG (CRSP) vs Li Auto Inc (LI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Li Auto Inc — how do they compare? Crispr Therapeutics AG trades at $51 (market cap $4.88B), while Li Auto Inc trades at $11.31 (market cap $10.71B). The key difference: Li Auto Inc is far larger — about 2.2× Crispr Therapeutics AG's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Li Auto Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Li Auto Inc for 101 Days on average.
| CRSP | LI | |
|---|---|---|
Market Cap | $4.88B | $10.71B |
Volume | 2,861,747 | 1,781,143 |
Sector | Health | Consumer Cyclical |
52-Week High | $74.92 | $23.61 |
52-Week Low | $44.34 | $10.69 |
Typical Hold Time | 77 Days | 101 Days |
Enterprise Value | $3.30B | $139.58M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% on the day, with a bearish technical signal and negative profitability metrics. The company reported no revenue in 2025 with a net loss of $581.60M, though recent earnings beat expectations in Q2 2026. Analyst sentiment remains positive with a $67.83 price target and 57.9% buy ratings, supported by upcoming clinical data catalysts for its gene-editing therapies.
The stock faces significant fundamental challenges with negative margins and cash burn, but strong analyst support and pipeline progress offer long-term potential. Key risks include clinical trial outcomes and commercialization execution, while institutional interest and positive media coverage provide near-term catalysts for investor consideration.
Li Auto (LI) trades at $10.99, down 0.92% on the day and near 52-week lows amid weak delivery numbers and earnings misses. The stock shows bearish technical signals with negative moving averages, though RSI indicates potential oversold conditions. Fundamentally, revenue declined to $112.31B in 2025 with net income margin turning negative at -4.4%, while valuation metrics show mixed signals with low P/S of 0.73 but high P/E of 99.38. Recent news highlights delivery moderation and new model launches as the company faces intense EV competition.
The outlook remains challenging with projected revenue decline to $104.8B and net loss of $4.6B in 2026. While analyst consensus suggests 38% upside to $15.18 price target, execution risks and cash burn pose significant headwinds. The stock's current discount to analyst targets presents opportunity, but requires careful monitoring of delivery recovery and margin improvement amid fierce Chinese EV competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Li Auto Inc
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 90,000 EVs in 2021, accounting for about 2.7% of China's passenger new energy vehicle market. Beyond Li One, the company will expand its product line, including both BEVs and PHEVs, to target a broader consumer base.
Read more on LI →
